Department of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Texas Oncology, Medical City Dallas, Dallas, Texas, USA.
World Neurosurg. 2022 Feb;158:132-138. doi: 10.1016/j.wneu.2021.11.042. Epub 2021 Nov 16.
The diagnosis of a contiguous, synchronous meningioma and central nervous system B-cell lymphoma is rare and associated with paradoxical treatment paradigms. We performed a scoping review of contiguous meningioma and B-cell lymphoma and included an additional illustrative case.
The OVID Medline and PubMed databases were systematically searched using the Preferred Reporting Items of Systematic Reviews and Meta-Analysis guidelines. Only human clinical reports of contiguous, synchronous meningioma and B-cell lymphoma were included. We concurrently detailed a representative case from our institution.
Nine case reports met our criteria, including the present case. The average age at diagnosis was 67.4 years. Patients showed a female-to-male predominance of 7:2. The diagnosis of synchronous intracranial tumors was not suspected or discovered until after surgical resection in 100% of cases. All meningiomas were grade I on histopathologic diagnosis, while lymphomas were distributed between diffuse large B-cell lymphoma (56%), metastatic lymphoma (22%), Burkitt lymphoma (11%), and follicular lymphoma (11%). All patients underwent surgical resection. Patients (n = 5) treated with adjuvant chemotherapy had evidence of longer progression-free survival (median 12 months; range, 3-18 months) than patients without adjuvant chemotherapy (n = 2; median 2 months; range, 1-3 months).
Contiguous, synchronous meningioma/B-cell lymphoma is a rare diagnosis that may appear as an inconspicuous solitary intracranial neoplasm on imaging. Based on the limited cases and current treatment of lymphoma, progression-free survival may be contingent on the prompt initiation of chemotherapy targeting the lymphoma rather than surgical resection of the meningeal mass. Providers should prioritize prompt medical management.
连续、同步脑膜瘤和中枢神经系统 B 细胞淋巴瘤的诊断较为罕见,且治疗方案相互矛盾。我们对连续脑膜瘤和 B 细胞淋巴瘤进行了范围界定的综述,并纳入了一个额外的说明性病例。
根据系统评价和荟萃分析的首选报告项目的指导方针,对 OVID Medline 和 PubMed 数据库进行了系统检索。仅纳入连续、同步脑膜瘤和 B 细胞淋巴瘤的人类临床报告。同时详细介绍了我们机构的一个代表性病例。
符合标准的病例报告有 9 篇,包括本病例。诊断时的平均年龄为 67.4 岁。患者的性别比例为女性:男性=7:2。100%的病例均在手术切除后才怀疑或发现同时存在颅内肿瘤。所有脑膜瘤的组织病理学诊断均为 I 级,而淋巴瘤分布在弥漫性大 B 细胞淋巴瘤(56%)、转移性淋巴瘤(22%)、伯基特淋巴瘤(11%)和滤泡性淋巴瘤(11%)之间。所有患者均接受了手术切除。接受辅助化疗的患者(n=5)无进展生存期更长(中位数 12 个月;范围 3-18 个月),而未接受辅助化疗的患者(n=2;中位数 2 个月;范围 1-3 个月)。
连续、同步脑膜瘤/B 细胞淋巴瘤是一种罕见的诊断,在影像学上可能表现为不明显的孤立性颅内肿瘤。基于目前有限的病例和淋巴瘤的治疗方法,无进展生存期可能取决于淋巴瘤的化疗是否及时启动,而不是脑膜瘤的手术切除。医生应优先考虑及时的医疗管理。